Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Sep 20, 2022 10:13am
147 Views
Post# 34973522

RE:RE:RE:RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo Clinic

RE:RE:RE:RE:RE:ONCY pelareorep + CAR-T therapy as explained by Mayo ClinicSpeaking of value .... Combining the 3 complementary therapies that are proving  to be synergistic and the addition of ONCY's pelareorep as part of the complement is proving to be an effective means to increase CAR-T persistence and durability, reverse an immunosuppressive tumor microenvironment (TME) for a more effective immune checkpoint inhibitor therapy, and is demonstrating the ability to overcome both antigen escape and resistance induced by T-cell immunotherapy and checkpoint blockade, respectively, in the treatment of solid tumors.
<< Previous
Bullboard Posts
Next >>